The DOI matches its Crossref record; 313 of the 313 references it cites were found in a registry or an index.
PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19
Open accessAbstract
This PharmGKB summary briefly discusses the CYP2C19 gene and current understanding of its function, regulation, and pharmacogenomic relevance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–313 of 313
A Novel Single Nucleotide Polymorphism Altering Stability and Activity of CYP2A6
Ariyoshi, N., Sawamura, Y.-I., & Kamataki, T. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.4422 · Cited by 103
Human CYP2C8: Structure, Substrate Specificity, Inhibitor Selectivity, Inducers and Polymorphisms
Lai, X.-S., Yang, L.-P., Li, X., Liu, J., Zhou, Z.-W., & Zhou, S.-F. (2009) · Current Drug Metabolism · doi:10.2174/138920009790711832 · Cited by 103
Pharmacokinetic and Toxicological Profile of Artemisinin Compounds: An Update
Medhi, B., Patyar, S., Rao, R. S., Prasad Byrav, D. S., & Prakash, A. (2009) · Pharmacology · doi:10.1159/000252658 · Cited by 101
Bergmann, T. K., Brasch‐Andersen, C., Gréen, H., Mirza, M. R., Pedersen, R. S., Nielsen, F., Skougaard, K., Wihl, J., Keldsen, N., Damkier, P., et al. (2010) · The Pharmacogenomics Journal · doi:10.1038/tpj.2010.19 · Cited by 100
PharmGKB summary: carbamazepine pathway
Thorn, C. F., Leckband, S. G., Kelsoe, J. R., Leeder, J. S., Müller, D. J., Klein, T. E., & Altman, R. B. (2011) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e328348c6f2 · Cited by 99
Self-citationInduction of polymorphic 4′‐hydroxylation of S‐mephenytoin by rifampicin.
Hh, Z., Anthony, L. B., Wood, A., et al. (1990) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1990.tb03799.x · Cited by 99
Effect of Rifampin on the Pharmacokinetics of Rosiglitazone in Healthy Subjects
Park, J. Y., Kim, K., Kang, M., et al. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.10.003 · Cited by 98
Ibeanu, G. C., Blaisdell, J. A., Ghanayem, B. I., et al. (1998) · Pharmacogenetics · doi:10.1097/00008571-199804000-00006 · Cited by 98
Three haplotypes associated with CYP2A6 phenotypes in Caucasians
Haberl, M., Anwald, B., Klein, K., Weil, R., Fu, C. T., Gepdíremen, A., Zanger, U. M., Meyer, U., & Wojnowski, L. (2005) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000171517.22258.f1 · Cited by 97
Projean, D., Morin, P.-E., Tu, T. M., et al. (2003) · Xenobiotica · doi:10.1080/0049825031000121608 · Cited by 97
Matimba, A., Del‐Favero, J., Broeckhoven, C. V., & Masimirembwa, C. M. (2009) · Human Genomics · doi:10.1186/1479-7364-3-2-169 · Cited by 96
Regulation of the cytochrome P450 2A genes
Su, T. (2004) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2003.11.029 · Cited by 93
Tornio, A., Niemi, M., Neuvonen, M., Laitila, J., Kalliokoski, A., Neuvonen, P. J., & Backman, J. T. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.34 · Cited by 92
Some Aspects of Genetic Polymorphism in the Biotransformation of Antidepressants
Brøsen, K. (2004) · Therapies · doi:10.2515/therapie:2004003 · Cited by 92
Gurbel, P. A., Tantry, U. S., Shuldiner, A. R., & Kereiakes, D. J. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.04.008 · Cited by 91
Self-citationParticipation of CYP2C8 and CYP3A4 in the N‐demethylation of imatinib in human hepatic microsomes
Nebot, N., Crettol, S., D’Esposito, F., Tattam, B. N., Hibbs, D. E., & Murray, M. T. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00946.x · Cited by 91
High and variable frequencies of CYP2C19 mutations
Kaneko, A., Lum, J. K., Yaviong, J., et al. (1999) · Pharmacogenetics · doi:10.1097/00008571-199910000-00005 · Cited by 90
Niemi, M., Tornio, A., Pasanen, M. K., Fredrikson, H., Neuvonen, P. J., & Backman, J. T. (2006) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-006-0133-z · Cited by 90
Effect of rifampicin on the pharmacokinetics of pioglitazone
Jaakkola, T., Backman, J. T., Neuvonen, M., Laitila, J., & Neuvonen, P. J. (2005) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02515.x · Cited by 89
Canova, C., Hashibe, M., Simonato, L., Nelis, M., Metspalu, A., Λάγιου, Π., Trichopoulos, D., Ahrens, W., Pigeot, I., Merletti, F., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2604 · Cited by 88
CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel
Hertz, D. L., Motsinger‐Reif, A. A., Drobish, A. A., Winham, S. J., McLeod, H. L., Carey, L., & Dees, E. C. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2054-0 · Cited by 87
Yu, K. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.114231 · Cited by 87
Rudberg, I., Hermann, M., Refsum, H., & Molden, E. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0533-3 · Cited by 86
Metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted
Yamanaka, H., Nakajima, M., Nishimura, K., Yoshida, R., Fukami, T., Katoh, M., & Yokoi, T. (2004) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2004.04.012 · Cited by 85
Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide
Bidstrup, T. B., Stilling, N. M., Damkier, P., Scharling, B., Thomsen, M. S., & Brøsen, K. (2004) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-004-0746-z · Cited by 84
Meunier, V., Bourrié, M., Julian, B., Marti, E., Guillou, F., Berger, Y., & Fabre, G. (2000) · Xenobiotica · doi:10.1080/004982500406426 · Cited by 83
Human Liver Expression of CYP2C8: Gender, Age, and Genotype Effects
Naraharisetti, S. B., Lin, Y. S., Rieder, M. J., Marciante, K. D., Psaty, B. M., Thummel, K. E., & Totah, R. A. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.031542 · Cited by 81
Tamaki, Y., Arai, T., Sugimura, H., Sasaki, T., Honda, M., Muroi, Y., Matsubara, Y., Kanno, S., Ishikawa, M., Hirasawa, N., et al. (2011) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-11-rg-046 · Cited by 80
A cytochrome P‐450 gene family mapped to human chromosome 19
Phillips, I. R., Shephard, E. A., Povey, S., Davis, M. B., Kelsey, G., MONTEIRO, M., West, L. F., & Cowell, J. K. (1985) · Annals of Human Genetics · doi:10.1111/j.1469-1809.1985.tb01702.x · Cited by 80
Onica, T., Nichols, K. D., Larin, M., Ng, L., Maslen, A., Dvořák, Z., Pascussi, J., Vilarem, M. J., Maurel, P., & Kirby, G. M. (2007) · Molecular Pharmacology · doi:10.1124/mol.107.039354 · Cited by 79
Filppula, A. M., Neuvonen, M., Laitila, J., Neuvonen, P. J., & Backman, J. T. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.048017 · Cited by 77
Honkalammi, J., Niemi, M., Neuvonen, P. J., & Backman, J. T. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.040931 · Cited by 77
Tanaka, Μ., Ohkubo, T., Otani, K., Suzuki, A., Kaneko, S., Sugawara, K., Ryokawa, Y., Hakusui, H., Yamamori, S., & Ishizaki, T. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90081-3 · Cited by 72
Rodríguez‐Antona, C., Niemi, M., Backman, J. T., Kajosaari, L. I., Neuvonen, P. J., Robledo, M., & Ingelman‐Sundberg, M. (2007) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500482 · Cited by 70
Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects
Rosenborg, S., Mwinyi, J., Andersson, M., Baldwin, R. M., Pedersen, R. S., Sim, S. C., Bertilsson, L., Ingelman‐Sundberg, M., & Eliasson, E. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0529-z · Cited by 68
Quaak, M., van Schayck, O. C. P., Knaapen, A. M., & van Schooten, F. (2009) · European Respiratory Journal · doi:10.1183/09031936.00056908 · Cited by 67
Elens, L., Vandercam, B., Yombi, J. C., Lison, D., Wallemacq, P. E., & Haufroid, V. (2010) · Pharmacogenomics · doi:10.2217/pgs.10.94 · Cited by 67
Komatsu, T., Yamazaki, H., Asahi, S., Gillam, E. M. J., Guengerich, F. P., Nakajima, M., & Yokoi, T. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15085-4 · Cited by 67
de Vos, A., van der Weide, J., & Loovers, H. M. (2010) · The Pharmacogenomics Journal · doi:10.1038/tpj.2010.39 · Cited by 66
Zhou, Q., Yu, X., Lin, H., Wang, L., Yun, Q., Hu, S., & Dm, W. (2009) · The Pharmacogenomics Journal · doi:10.1038/tpj.2009.31 · Cited by 66
Blanco‐Fernández, G., Martínez, C., Ladero, J. M., García‐Martín, E., Taxonera, C., Garcia-Gamito, F. J., Díaz‐Rubio, M., & Agúndez, J. A. G. (2008) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3282f305a9 · Cited by 66
Gao, Y., Liu, D., Wang, H., Zhu, J., & Chen, C. (2010) · Xenobiotica · doi:10.3109/00498254.2010.487163 · Cited by 66
Ho, M., Mwenifumbo, J. C., Zhao, B., Gillam, E. M. J., & Tyndale, R. F. (2008) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3282f3606e · Cited by 65
Kasperska−Zając, A., Brzoza, Z., & Rogala, B. (2008) · Recent Patents on Inflammation & Allergy Drug Discovery · doi:10.2174/187221308783399306 · Cited by 65
Molecular Genetics of Nicotine Metabolism
Mwenifumbo, J. C., & Tyndale, R. F. (2009) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-69248-5_9 · Cited by 64
Mechanism-Based Inactivation of CYP2C8 by Gemfibrozil Occurs Rapidly in Humans
Honkalammi, J., Niemi, M., Neuvonen, P. J., & Backman, J. T. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.358 · Cited by 64
Amiodarone N‐Deethylation by CYP2C8 and its Variants, CYP2C8*3 and CYP2C8 P404A
Soyama, A., Hanioka, N., Saito, Y., Murayama, N., Ando, M., Ozawa, S., & Sawada, J. (2002) · Pharmacology & Toxicology · doi:10.1034/j.1600-0773.2002.910404.x · Cited by 64
Kancko, A., Bergqvist, Y., Taleo, G. K., Kobayakawa, T., Ishizaki, T., & rkman, A. B. (1999) · Pharmacogenetics · doi:10.1097/00008571-199906000-00006 · Cited by 64
CYP2A6Genotype, Phenotype, and the Use of Nicotine Metabolites as Biomarkers duringAd libitumSmoking
Malaiyandi, V., Goodz, S. D., Sellers, E. M., & Tyndale, R. F. (2006) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-05-0723 · Cited by 64
Mwinyi, J., Cavaco, I., Pedersen, R. S., Persson, A., Burkhardt, S., Mkrtchian, S., & Ingelman‐Sundberg, M. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.065540 · Cited by 64
Easterbrook, J. D., Fackett, D., & Li, A. P. (2001) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(01)00159-4 · Cited by 63
Fujita, K., Yamamoto, W., Endo, S., Endo, H., Nagashima, F., Ichikawa, W., Tanaka, R., Miya, T., Araki, K., Kodama, K., et al. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00773.x · Cited by 63
Mwenifumbo, J. C., Lessov-Schlaggar, C. N., Zhou, Q., Krasnow, R. E., Swan, G. E., Benowitz, N. L., & Tyndale, R. F. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100246 · Cited by 63
Genetic Determinants of Mycophenolate-Related Anemia and Leukopenia After Transplantation
Jacobson, P. A., Schladt, D., Oetting, W. S., Leduc, R. E., Guan, W., Matas, A. J., Lamba, V., Mannon, R. B., Julian, B. A., & Israni, A. K. (2010) · Transplantation · doi:10.1097/tp.0b013e318200e971 · Cited by 63
Karonen, T., Filppula, A. M., Laitila, J., Niemi, M., Neuvonen, P. J., & Backman, J. T. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.73 · Cited by 61
Ishikawa, C., Ozaki, H., Nakajima, T., Ishii, T., Kanai, S., ANJO, S., Shirai, K., & Inoue, I. (2004) · Journal of Human Genetics · doi:10.1007/s10038-004-0188-6 · Cited by 60
Isolation and sequence of a human cytochrome P-450 cDNA clone.
Phillips, I. R., Shephard, E. A., Ashworth, A., & Rabin, B. R. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.4.983 · Cited by 59
Effect of gemfibrozil on the pharmacokinetics of pioglitazone
Deng, L., Wang, F., & Huan-de, L. (2005) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-005-0042-6 · Cited by 59
Expanding the Antimalarial Drug Arsenal—Now, But How?
Grimberg, B. T., & Mehlotra, R. K. (2011) · Pharmaceuticals · doi:10.3390/ph4050681 · Cited by 59
Murai, K., Yamazaki, H., Nakagawa, K., Kawai, R., & Kamataki, T. (2009) · Xenobiotica · doi:10.3109/00498250903171395 · Cited by 57
Associations ofCYP2A6genotype with smoking behaviors in southern China
Liu, T., David, S. P., Tyndale, R. F., Wang, H., Zhou, Q., Ding, P., He, Y., Yu, X., Chen, W., Crump, C., et al. (2010) · Addiction · doi:10.1111/j.1360-0443.2010.03353.x · Cited by 55
Huang, S., Cook, D. G., Hinks, L. J., Chen, X., Ye, S., Gilg, J. A., Jarvis, M. J., Whincup, P. H., & Day, I. N. M. (2005) · Pharmacogenetics and Genomics · doi:10.1097/01213011-200512000-00002 · Cited by 55
Park, S. R., Kong, S.-Y., Nam, B., Choi, I. J., Kim, C. G., Lee, J. Y., Cho, S., Kim, Y., Ryu, K. W., Lee, J. H., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.24 · Cited by 55
Filppula, A. M., Laitila, J., Neuvonen, P. J., & Backman, J. T. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.037689 · Cited by 55
CYP2A6Polymorphisms and Risk for Tobacco-Related Cancers
Rossini, A., Simão, T. D. A., Albano, R. M., & Pinto, L. F. R. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.11.1737 · Cited by 55
Characterization of the Genetic Profile of CYP2C19 in Two South African Populations
Drögemöller, B. I., Wright, G. E. B., Niehaus, D. J. H., Koen, L., Malan‐Müller, S., Silva, D. M. D., Hillermann–Rebello, R., Grange, A. M. L., Venter, M., & Warnich, L. (2010) · Pharmacogenomics · doi:10.2217/pgs.10.90 · Cited by 53
Aquilante, C. L., Bushman, L. R., Knutsen, S. D., Burt, L. E., Rome, L. C., & Kosmiski, L. A. (2008) · Human Genomics · doi:10.1186/1479-7364-3-1-7 · Cited by 53
Koudsi, N. A., Ahluwalia, J. S., Lin, S., Sellers, E. M., & Tyndale, R. F. (2009) · The Pharmacogenomics Journal · doi:10.1038/tpj.2009.11 · Cited by 52
Koudsi, N. A., & Tyndale, R. F. (2010) · Xenobiotica · doi:10.3109/00498251003713958 · Cited by 51
A Novel Duplication Type of CYP2A6 Gene in African-American Population
Fukami, T., Nakajima, M., Yamanaka, H., Fukushima, Y., McLeod, H. L., & Yokoi, T. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.013557 · Cited by 50
Hammond, D. K., Bjercke, R. J., Langone, J. J., & Strobel, H. W. (1991) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08898-1 · Cited by 50
Jeong, S., Woo, M. M., Flockhart, D. A., & Desta, Z. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-0935-7 · Cited by 49
Gemfibrozil Is a Strong Inactivator of CYP2C8 in Very Small Multiple Doses
Honkalammi, J., Niemi, M., Neuvonen, P. J., & Backman, J. T. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.313 · Cited by 49
Peamkrasatam, S., Sriwatanakul, K., Kiyotani, K., Fujieda, M., Yamazaki, H., Kamataki, T., & Yoovathaworn, K. (2006) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.21.475 · Cited by 49
Role of hepatocyte nuclear factor 3γ in the expression of human CYP2C genes
Bort, R., Gómez‐Lechón, M. J., Castell, J. V., & Jover, R. (2004) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2004.03.032 · Cited by 48
Kaspera, R., Naraharisetti, S. B., Evangelista, E. A., Marciante, K. D., Psaty, B. M., & Totah, R. A. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.06.027 · Cited by 46
Schenk, P. W., van Vliet, M., Mathôt, R. A. A., van Gelder, T., Vulto, A. G., van Fessem, M., Rij, S. V.-V., Lindemans, J. W., Bruijn, J. A., & van Schaik, R. H. N. (2009) · The Pharmacogenomics Journal · doi:10.1038/tpj.2009.50 · Cited by 46
Lee, S., Kim, W., Kim, H., Shon, J., Lee, S. S., & Shin, J. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.028175 · Cited by 46
Sissung, English, B. C., Baum, Adelberg, Sissung, Kluetz, Dahut, Price, & Figg (2010) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s14303 · Cited by 45
Morinobu, S., Tanaka, T., Kawakatsu, S., Totsuka, S., Koyama, E., CHIBA, K., Ishizaki, T., & Kubota, T. (1997) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.1997.tb02593.x · Cited by 45
Pedersen, R. S., Damkier, P., & Brøsen, K. (2006) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02706.x · Cited by 45
Association of CYP2A6 Gene Deletion with Cigarette Smoking Status in Japanese Adults.
Ando, M., Hamajima, N., Ariyoshi, N., Kamataki, T., Matsuo, K., & Ohno, Y. (2003) · Journal of Epidemiology · doi:10.2188/jea.13.176 · Cited by 44
The impact ofCYP2C8polymorphism and grapefruit juice on the pharmacokinetics of repaglinide
Bidstrup, T. B., Damkier, P., Olsen, A. K., Ekblom, M., Karlsson, A., & Brøsen, K. (2005) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02516.x · Cited by 43
Effect of the CYP2C8 Genotype on the Pharmacokinetics and Pharmacodynamics of Repaglinide
Tomalik‐Scharte, D., Fuhr, U., Hellmich, M., Frank, D., Doroshyenko, O., Jetter, A., & Stingl, J. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.036921 · Cited by 43
Koyama, E., Tanaka, T., Chiba, K., Kawakatsu, S., Morinobu, S., Totsuka, S., & Ishizaki, T. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199608000-00003 · Cited by 42
Gambier, N., Batt, A. G., Bastien, B., Pfister, M., Siest, G., & Visvikis‐Siest, S. (2005) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500314 · Cited by 40
Wang, H., Bian, T., Liu, D., Jin, T., Chen, Y., Lin, A., & Chen, C. (2011) · Pharmacogenomics · doi:10.2217/pgs.10.202 · Cited by 38
Population pharmacokinetic analysis of letrozole in Japanese postmenopausal women
Tanii, H., Shitara, Y., & Horie, T. (2011) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-011-1042-3 · Cited by 35
Pan-Zhou, X.-R., Cretton-Scott, E., Zhou, X., Yang, M., Lasker, J. M., & Sommadossi, J. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00538-8 · Cited by 34
Rana, R., Chen, Y., Ferguson, S., Kissling, G. E., Surapureddi, S., & Goldstein, J. A. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.030387 · Cited by 34
Filppula, A. M., Tornio, A., Niemi, M., Neuvonen, P. J., & Backman, J. T. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.92 · Cited by 33
Stage, T. B., Christensen, M. M. H., Feddersen, S., Beck‐Nielsen, H., & Brøsen, K. (2013) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32835f91fc · Cited by 33
Structural and functional insights into polymorphic enzymes of cytochrome P450 2C8
Jiang, H., Zhong, F., Sun, L., Feng, W., Huang, Z., & Tan, X. (2010) · Amino Acids · doi:10.1007/s00726-010-0743-8 · Cited by 32
The transcription factor GATA-4 regulates cytochrome P4502C19 gene expression
Mwinyi, J., Hofmann, Y., Pedersen, R. S., Nekvindová, J., Cavaco, I., Mkrtchian, S., & Ingelman‐Sundberg, M. (2010) · Life Sciences · doi:10.1016/j.lfs.2010.02.021 · Cited by 31
Romkes, M., Faletto, M. B., Blaisdell, J. A., Raucy, J. L., & Goldstein, J. A. (1993) · Biochemistry · doi:10.1021/bi00056a025 · Cited by 31
In vivo evaluation of CYP2A6 and xanthine oxidase enzyme activities in the Serbian population
Djordjević, N., Carrillo, J. A., Gervasini, G., Јаnkovic, S., & Aklillu, E. (2010) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-010-0785-6 · Cited by 30
Muthiah, Y. D., Lee, W. L., Teh, L. K., Ong, C. E., & Ismail, R. (2005) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2005.00653.x · Cited by 30
Kimura, M., Yamazaki, H., Fujieda, M., Kiyotani, K., Honda, G., Saruwatari, J., Nakagawa, K., Ishizaki, T., & Kamataki, T. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.004796 · Cited by 30
Species differences in coumarin metabolism: a molecular modelling evaluation of CYP2A interactions
Lewis, D. F. V., & Lake, B. G. (2002) · Xenobiotica · doi:10.1080/00498250210128693 · Cited by 29
Phenotypic CYP2A6 variation and the risk of pancreatic cancer.
Kadlubar, S. A., ANDERSON, J. P., Sweeney, C., Gross, M. D., Lang, N. P., Kadlubar, F. F., & Anderson, K. E. (2009) · PubMed · Cited by 29
Haplotype block structure of the cytochrome P450 CYP2C gene cluster on chromosome 10
Walton, R. T., Kimber, M., Rockett, K. A., Trafford, C., Kwiatkowski, D. P., & Sirugo, G. (2005) · Nature Genetics · doi:10.1038/ng0905-915 · Cited by 28
The Role of Human CYP2C8 and CYP2C9 Variants in Pioglitazone MetabolismIn Vitro
Muschler, E., Lal, J., Jetter, A., Rattay, A., Zanger, U. M., Zadoyan, G., Fuhr, U., & Kirchheiner, J. (2009) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2009.00457.x · Cited by 28
Endo, T., Ban, M., Hirata, K., Yamamoto, A., Hara, Y., & Momose, Y. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.013425 · Cited by 24
Yeo, C., Lee, S., Lee, S. S., Bae, S. K., Kim, E. Y., Shon, J., Rhee, B. D., & Shin, J. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.035899 · Cited by 24
Inoue, K., Inazawa, J., Suzuki, Y., Shimada, T., Yamazaki, H., Guengerich, F. P., & Abe, T. (1994) · The Japanese Journal of Human Genetics · doi:10.1007/bf01874052 · Cited by 19
Kadam, R. S., Bourne, D. W. A., Kompella, U. B., et al. (2013) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b12-00657 · Cited by 18
Effect of cigarette smoking on coumarin metabolism in humans
Poland, R. E., Pechnick, R. N., Cloak, C. C., Wan, Y. Y., Nuccio, I., & Lin, K. (2000) · Nicotine & Tobacco Research · doi:10.1080/713688151 · Cited by 17
Kumar, A. S. A., Uppugunduri, C. R. S., Umamaheswaran, G., Ramu, P., Ramasamy, K., Shewade, D. G., Balachandar, J., & Chandrasekaran, A. (2011) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2010.0170 · Cited by 16
Bouamar, R., Elens, L., Shuker, N., van Schaik, R. H. N., Weimar, W. W., Hesselink, D. A., & van Gelder, T. (2012) · Transplantation · doi:10.1097/tp.0b013e3182488bb4 · Cited by 15
Kim, M., Lee, J., Oh, K.-S., Choi, C., Kim, K. H., Han, W. S., Yoon, C. N., Chung, E. S., Kim, D., & Shin, J. (2013) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-13-rg-019 · Cited by 14
Pedersen, R. S., Christensen, M. M. H., & Brøsen, K. (2012) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-012-1272-z · Cited by 13
Moon, Y. J., Zhang, S., Brazeau, D. A., & Morris, M. E. (2007) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200600156 · Cited by 12
Iwahashi, K., & Aoki, J. (2009) · Drug and Chemical Toxicology · doi:10.1080/01480540903203976 · Cited by 6
Cited by
Scott, S. A., Sangkuhl, K., Stein, C. M., Hulot, J.-S., Mega, J. L., Roden, D. M., Klein, T. E., Sabatine, M. S., Johnson, J. A., & Shuldiner, A. R. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.105 · Cited by 962
Self-citationBiochemical verification of tobacco use and abstinence: 2019 update
Benowitz, N. L., Bernert, J. T., Foulds, J., Hecht, S. S., Jacob, P., Jarvis, M. J., Joseph, A., Oncken, C., & Piper, M. E. (2020) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntz132 · Cited by 619
Moriyama, B., Obeng, A. O., Barbarino, J., Penzak, Sr., Henning, S., Scott, S., Agúndez, J., Wingard, Jr., McLeod, H., Klein, T., et al. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.583 · Cited by 404
Self-citationApplications of CYP450 Testing in the Clinical Setting
Samer, C. F., Lorenzini, K. I., Rollason, V., Daali, Y., & Desmeules, J. A. (2013) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-013-0028-5 · Cited by 354
Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine
El Rouby, N., Lima, J. J., & Johnson, J. A. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1461835 · Cited by 263
Metadata
- Authors
- Scott, S. A., Sangkuhl, K., Shuldiner, A. R., Hulot, J.-S., Thorn, C. F., Altman, R. B., & Klein, T. E.
- Venue
- Pharmacogenetics and Genomics
- Published
- 2012-02
- Volume
- 22
- Issue
- 2
- Pages
- 159-165
- ISSN
- 1744-6872 (ISSN-L)
- OpenAlex
- W2025995483
- Cited by
- 261
- References
- 313
- FWCI
- 8.97
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.